Taysha Gene Therapies
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $1,986 | $2,302 | $2,022 |
Gross Profit | -286 | 1,986 | 2,302 | 2,022 |
EBITDA | -32,431 | -26,588 | -21,227 | -18,459 |
EBIT | -32,717 | -26,865 | -21,510 | -18,763 |
Net Income | -32,732 | -26,882 | -21,529 | -18,785 |
Net Change In Cash | 0 | 1,986 | 2,302 | 2,022 |
Free Cash Flow | -24,274 | -20,184 | -22,398 | -18,306 |
Cash | 297,344 | 312,761 | 116,593 | 139,036 |
Basic Shares | 353,309 | 297,988 | 269,306 | 204,943 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $8,333 | $15,451 | $2,502 | $0 |
Gross Profit | 8,333 | 15,451 | 14 | -492 |
EBITDA | -87,951 | -105,197 | -159,729 | -172,603 |
EBIT | -89,196 | -106,568 | -162,216 | -173,095 |
Net Income | -89,298 | -111,566 | -166,014 | -174,523 |
Net Change In Cash | 8,333 | 15,451 | 2,502 | 0 |
Free Cash Flow | -81,599 | -80,387 | -113,259 | -138,596 |
Cash | 139,036 | 143,940 | 87,880 | 149,103 |
Basic Shares | 250,134 | 116,121 | 43,952 | 37,650 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.08 |
2025-06-30 | -$0.08 |
2025-03-31 | -$0.07 |
